144 related articles for article (PubMed ID: 19177695)
41. That which must not, can not be... A reply to the EChA and EDF responses to the REACH analysis of animal use and costs.
Hartung T; Rovida C
ALTEX; 2009; 26(4):307-11. PubMed ID: 20957835
[No Abstract] [Full Text] [Related]
42. Lead in your lipstick and other scary stories.
Morris K
Ohio Nurses Rev; 2012; 87(2):6-7. PubMed ID: 22533100
[No Abstract] [Full Text] [Related]
43. Safety assessment of cosmetic ingredients present in technical information files of finished products.
Rogiers V; Pauwels M
Curr Probl Dermatol; 2008; 36():94-114. PubMed ID: 18806455
[No Abstract] [Full Text] [Related]
44. REACH: impact on the US cosmetics industry?
Pouillot A; Polla B; Polla A
J Cosmet Dermatol; 2009 Mar; 8(1):3-7. PubMed ID: 19250158
[TBL] [Abstract][Full Text] [Related]
45. [EU-Cosmetics: timetables for the replacement of animal experiments].
Ruhdel IW
ALTEX; 2005; 22(2):117-9. PubMed ID: 15953967
[TBL] [Abstract][Full Text] [Related]
46. European Commission--Directorate General DG XXIV Consumer Policy and Consumer Health Protection. Notes of Guidance for testing of cosmetic ingredients for their safety evaluation (Second Revision). Adopted: 20 December 1996. Revised: 16 January 1997. The Scientific Committee on Cosmetology of the European Commission.
Food Chem Toxicol; 1999 Apr; 37(4):357-85. PubMed ID: 10418954
[No Abstract] [Full Text] [Related]
47. EU: final ban on animal experiments for cosmetic ingredients implemented.
ALTEX; 2013; 30(2):268-9. PubMed ID: 23805431
[No Abstract] [Full Text] [Related]
48. The critical review of methodologies and approaches to assess the inherent skin sensitization potential (skin allergies) of chemicals. Part III.
Thyssen JP; Giménez-Arnau E; Lepoittevin JP; Menné T; Boman A; Schnuch A
Contact Dermatitis; 2012 Apr; 66 Suppl 1():53-70. PubMed ID: 22380842
[TBL] [Abstract][Full Text] [Related]
49. Paving the way for application of next generation risk assessment to safety decision-making for cosmetic ingredients.
Dent MP; Vaillancourt E; Thomas RS; Carmichael PL; Ouedraogo G; Kojima H; Barroso J; Ansell J; Barton-Maclaren TS; Bennekou SH; Boekelheide K; Ezendam J; Field J; Fitzpatrick S; Hatao M; Kreiling R; Lorencini M; Mahony C; Montemayor B; Mazaro-Costa R; Oliveira J; Rogiers V; Smegal D; Taalman R; Tokura Y; Verma R; Willett C; Yang C
Regul Toxicol Pharmacol; 2021 Oct; 125():105026. PubMed ID: 34389358
[TBL] [Abstract][Full Text] [Related]
50. Predicting skin sensitization potential and inter-laboratory reproducibility of a human Cell Line Activation Test (h-CLAT) in the European Cosmetics Association (COLIPA) ring trials.
Sakaguchi H; Ryan C; Ovigne JM; Schroeder KR; Ashikaga T
Toxicol In Vitro; 2010 Sep; 24(6):1810-20. PubMed ID: 20510347
[TBL] [Abstract][Full Text] [Related]
51. Opinion of the scientific committee on consumer safety (SCCS) - Final opinion on Polyaminopropyl Biguanide (PHMB) in cosmetic products - Submission III.
; Rogiers V;
Regul Toxicol Pharmacol; 2017 Aug; 88():328-329. PubMed ID: 28483711
[No Abstract] [Full Text] [Related]
52. Opinion of the Scientific Committee on Consumer safety (SCCS) - Revision of the opinion on the safety of the use of titanium dioxide, nano form, in cosmetic products.
; Chaudhry Q
Regul Toxicol Pharmacol; 2015 Nov; 73(2):669-70. PubMed ID: 26363206
[No Abstract] [Full Text] [Related]
53. The feasibility of replacing animal testing for assessing consumer safety: a suggested future direction.
Fentem J; Chamberlain M; Sangster B
Altern Lab Anim; 2004 Dec; 32(6):617-23. PubMed ID: 15757499
[TBL] [Abstract][Full Text] [Related]
54. The seventh amendment to the cosmetics directive: what does DG enterprise want from ECVAM?
Schumann R
Altern Lab Anim; 2002 Dec; 30 Suppl 2():213-4. PubMed ID: 12513678
[TBL] [Abstract][Full Text] [Related]
55. Consumers' lack of understanding of customized cosmetics made on the spot and implications for regulations and controls.
Kim HW; Seok YS; Lee HG; Song MK; Rhee MS
Regul Toxicol Pharmacol; 2021 Aug; 124():104979. PubMed ID: 34197870
[TBL] [Abstract][Full Text] [Related]
56. [The European regulation for cosmetics : Legislative aspect from the German point of view].
Butschke A; Dross A
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jun; 53(6):606-9. PubMed ID: 20458455
[TBL] [Abstract][Full Text] [Related]
57. EU borderline cosmetic products review of current regulatory status.
Morganti P; Paglialunga S
Clin Dermatol; 2008; 26(4):392-7. PubMed ID: 18691521
[TBL] [Abstract][Full Text] [Related]
58. Toxicokinetics and metabolism.
Coecke S; Blaauboer BJ; Elaut G; Freeman S; Freidig A; Gensmantel N; Hoet P; Kapoulas VM; Ladstetter B; Langley G; Leahy D; Mannens G; Meneguz A; Monshouwer M; Nemery B; Pelkonen O; Pfaller W; Prieto P; Proctor N; Rogiers V; Rostami-Hodjegan A; Sabbioni E; Steiling W; van de Sandt JJ
Altern Lab Anim; 2005 Jul; 33 Suppl 1():147-75. PubMed ID: 16194147
[No Abstract] [Full Text] [Related]
59. The SCCS scientific advice on the safety of nanomaterials in cosmetics.
; Bernauer U; Bodin L; Chaudhry Q; Coenraads PJ; Dusinska M; Gaffet E; Panteri E; Rogiers V; Rousselle C; Stepnik M; Vanhaecke T; Wijnhoven S; ; von Goetz N; de Jong WH
Regul Toxicol Pharmacol; 2021 Nov; 126():105046. PubMed ID: 34560169
[TBL] [Abstract][Full Text] [Related]
60. [Cosmetic products : Safety aspects].
Platzek T; Krätke R; Schulz C
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jun; 53(6):610-4. PubMed ID: 20464352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
